Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity

Award Number: R41CA232779
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/20/2018
PERIOD OF PERFORMANCE END DATE: 07/31/2022

Group Awards By:

View Award Description

Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity - Three CDK4/6 inhibitors were recently approved to treat breast cancer (BrCA) in combination regiments. Despite significant clinical activity, treatment of BrCA patients with these combinations does not result in a durable response. Hence, there is an unmet medical need to develop targeted therapeutic agents which will augment the activity of CDK4/6 inhibitors in BrCA and other CDK4/6-cyclin D-Myc dependent malignancies. A recent report demonstrated that PI3 kinase (PI3K) inhibition is critical to maintain CDK4/6 sensitivity of tumor cells. Hence, our central hypothesis to be tested in this proposal is that combined triple inhibition of CDK4/6, PI3K and BRD4 with one small molecule, SRX3177, will be more efficacious and less toxic than combining three separate inhibitors. An innovative component of our proposal is that we have developed in silico guiding models to design and then synthesized SRX317, the first small-molecule inhibitory chemotype that potently inhibits these three important targets, CDK4/6, PI-3K and BRD4 simultaneously in the same cell (preliminary results). We have demonstrated “proof of concept” that SRX3177: 1) inhibits all three targets at nM potency, 2) inhibits all three targets in cell-based assays, 3) displays 20-fold greater efficacy in cell based assays for IC50 determination, 4) displays 40-fold less toxicity in normal cells, and most importantly 5) demonstrates efficacy but lacks detectable toxicity in vivo as compared to the high mortality rate observed in mice treated with 3 separate drugs of equal potency, e.g., Palbociclib (CDK4/6), BKM120 (PI3K) and JQ1 (BRD4). The significance of our proposal lies in our capacity to provide an optimizable promising single anticancer agent which will potently inhibit CDK4/6 Cyclin D and Myc via multiple orthogonal signaling mechanisms and inhibit survival signaling by blocking the PI3K pathway. This proposal will evaluate this approach by achieving the following aims setting the stage for phase II efforts to optimize the expected triple inhibitory lead compound(s) to a clinical candidate: Aim (Task) #1. Develop a potent CDK4/6 inhibitor with inhibitory properties against PI3K and BRD4. Approach: In silico design and modeling of 144 chemotypes to select 20 SRX3177 analogs. Aim (Task) #2. Characterize the 20 new compounds. Approach: Determine their CDK4/6, BRD4 and PI3K inhibition profiles and ADME properties. Aim (Task) #3. Demonstrate triple inhibitor is superior to use of three separate inhibitors in vivo. Approach: Compare toxicity and efficacy of triple inhibitors versus individual CDK4/6 + PI3K + BRD4 inhibitory conditions in vitro and in vivo. The significance of this research is it will greatly expand the efficacy of CDK4/6 inhibition against cyclin D/Myc dependent malignant diseases. This innovative approach attacks cancer blocking three distinct, cancer-driving orthogonal mechanisms with a single compound with greater safety in vivo challenging the one-drug one-target dogma.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2018	SIGNALRX PHARMACEUTICALS, INC.	2215 PILGRIM MILL CIR	CUMMING	GA	30041	FORSYTH	USA	Cancer Treatment Research	000	1	6/13/2023	NEW	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2018	SIGNALRX PHARMACEUTICALS, INC.	2215 PILGRIM MILL CIR	CUMMING	GA	30041	FORSYTH	USA	Cancer Treatment Research	000	1	9/24/2021	NEW	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2018	SIGNALRX PHARMACEUTICALS, INC.	12545 EL CAMINO REAL UNIT C	SAN DIEGO	CA	92130	SAN DIEGO	USA	Cancer Treatment Research	000	1	6/29/2020	NEW	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $299,738 )
2018	2018	SIGNALRX PHARMACEUTICALS, INC.	12545 EL CAMINO REAL	SAN DIEGO	CA	92130	SAN DIEGO	USA	Cancer Treatment Research	000	1	8/20/2018	NEW	$299,738
														Subtotal = $299,738

Grand Total All Awards = $299,738

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity

Award Number: R41CA232779

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/20/2018

PERIOD OF PERFORMANCE END DATE: 07/31/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer